Active
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma:
Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Drug:
Selumetinib in Combination with Sirolimus
Accrual Status:
Not Yet Recruiting
Overall Study Principal Investigator:
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Health System
Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute
Pediatric Oncologist
Children’s National Health System
Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute